Skip to content

Author

M. S. Hofman

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Kidney impairment post 177Lu-PSMA radioligand therapy in metastatic prostate cancer.

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is a novel theranostic approved for the treatment of metastatic castration-resistant prostate cancer. It has been understood to have a low risk of mild nephrotoxicity, although the emergence of delayed or acute renal toxicity is variably descr...

Jesse Osbourne, M. S. Hofman, Irene Ruderman · 0 citations
Open access Sep 2026

Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy.

The PRINCE trial showed the clinical activity for 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration-resistant prostate cancer. To refine patient selection and improve response monitoring strategies to this combination, we investigated candidate tumor-intrinsic biomarkers of treatment response a...

S. Tolmeijer, Edmond M. Kwan, Andrei Gafita et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.